N
NGM Biopharmaceuticals
A clinical-stage biopharmaceutical company which engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases
About NGM Biopharmaceuticals
NGM Bio is a biopharmaceutical company dedicated to discovering and developing novel medicines aimed at transforming the lives of patients affected by serious diseases. The company employs a biology-centric drug discovery approach, integrating complex disease biology with protein engineering to generate proprietary insights. These insights are used to create promising product candidates that can quickly advance into proof-of-concept studies. NGM Bio's research and development engine is highly productive, with all therapeutic candidates in its pipeline originating from its in-house discovery efforts. The company serves patients with unmet medical needs and operates in the biopharmaceutical market. NGM Bio's business model focuses on leveraging its scientific expertise to develop and commercialize new therapies, thereby generating revenue through the successful advancement and eventual market introduction of its drug candidates. Currently, the company has four programs in active clinical development, supported by a strong financial position and a healthy cash runway. Keywords: biopharmaceutical, drug discovery, protein engineering, disease biology, patient needs, clinical development, research, development, medicines, therapeutic candidates.
Source: Dealroom company dataAt a glance
- Founded
- 2007
- Headquarters
- South San Francisco, United States
- Listing
- IPO 2019
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
The Column Group- PPProspect Venture Partners
Rho Ventures
Rho Capital Partners
Series B and later3 investors entered at this stage
TopSpin Marketing Group, Inc.
Solon Mack Capital
Merck & Co.
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
41 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about NGM Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NGM Biopharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.